메뉴 건너뛰기




Volumn 21, Issue 7, 2014, Pages 894-910

VEGF signal system: The application of antiangiogenesis

Author keywords

Anticancer agents; Kinase inhibitors; Signal pathways; VEGF; VEGFR

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AXITINIB; BEVACIZUMAB; BRIVANIB; CABOZANTINIB; CEDIRANIB; CETUXIMAB; FORETINIB; LENVATINIB; LESTAURTINIB; LINIFANIB; MESSENGER RNA; MONOCLONAL ANTIBODY IMC 1C11; MOTESANIB; NINTEDANIB; PANITUMUMAB; PAZOPANIB; PEGAPTANIB; PHOSPHATIDYLINOSITOL 3 KINASE; RANIBIZUMAB; SEMAXANIB; SORAFENIB; SUNITINIB; TIVOZANIB; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VATALANIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN;

EID: 84893550895     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113206660264     Document Type: Article
Times cited : (50)

References (94)
  • 1
    • 79952284127 scopus 로고    scopus 로고
    • Hallmarks of cancer: The next generation
    • Hanahan, D.; Weinberg, R. A. Hallmarks of Cancer: The Next Generation. Cell, 2011, 144(5), 646-674.
    • (2011) Cell , vol.144 , Issue.5 , pp. 646-674
    • Hanahan, D.1    Weinberg, R.A.2
  • 2
    • 85013312416 scopus 로고
    • Tumor angiogenesis: Therapeutic implications
    • Folkman, J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med., 1971, 285(21), 1182-1186.
    • (1971) N. Engl. J. Med. , vol.285 , Issue.21 , pp. 1182-1186
    • Folkman, J.1
  • 3
    • 0034092011 scopus 로고    scopus 로고
    • Tumor angiogenesis: Past, present and the near future
    • Kerbel, R. S. Tumor angiogenesis: past, present and the near future. Carcinogenesis, 2000, 21(3), 505-515.
    • (2000) Carcinogenesis , vol.21 , Issue.3 , pp. 505-515
    • Kerbel, R.S.1
  • 4
    • 0031969264 scopus 로고    scopus 로고
    • Angiogenesis and tumor metastasis
    • Bruce R. Zetter. Angiogenesis and tumor metastasis. Annu. Rev. Med., 1998, 49, 407-424.
    • (1998) Annu. Rev. Med. , vol.49 , pp. 407-424
    • Bruce, R.Z.1
  • 5
    • 0030576517 scopus 로고    scopus 로고
    • Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
    • Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 1996, 86(3), 353-364.
    • (1996) Cell , vol.86 , Issue.3 , pp. 353-364
    • Hanahan, D.1    Folkman, J.2
  • 7
    • 33645971968 scopus 로고    scopus 로고
    • Antiangiogenesis drug design: Multiple pathways targeting tumor vasculature
    • Zhong, H.; Bowen, J. P. Antiangiogenesis Drug Design: Multiple Pathways Targeting Tumor Vasculature. Curr. Med. Chem., 2006, 13(8), 849-862.
    • (2006) Curr. Med. Chem. , vol.13 , Issue.8 , pp. 849-862
    • Zhong, H.1    Bowen, J.P.2
  • 8
    • 0038012338 scopus 로고    scopus 로고
    • Angiogenesis inhibitors under study for the treatment of lung cancer
    • Shepherd, F. A.; Sridhar, S. S. Angiogenesis inhibitors under study for the treatment of lung cancer. Lung Cancer, 2003, 41, S63-S72.
    • (2003) Lung Cancer , vol.41
    • Shepherd, F.A.1    Sridhar, S.S.2
  • 10
    • 0032907687 scopus 로고    scopus 로고
    • Vascular endothelial growth factor (vegf) and its receptors
    • Neufeld, G.; Cohen, T.; Gengrinovitch, S.; Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J.,1999, 13(1), 9-22.
    • (1999) FASEB J. , vol.13 , Issue.1 , pp. 9-22
    • Neufeld, G.1    Cohen, T.2    Gengrinovitch, S.3    Poltorak, Z.4
  • 11
    • 0031572858 scopus 로고    scopus 로고
    • The crystal structure of vascular endothelial growth factor (vegf) refined to 1.93 å resolution: Multiple copy flexibility and receptor binding
    • Yv Muller, Y. A.; Christinger, H. W.; Keyt, B. A.; de Vos, A. M. The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 Å resolution: multiple copy flexibility and receptor binding. Structure, 1997, 5(10), 1325-1327.
    • (1997) Structure , vol.5 , Issue.10 , pp. 1325-1327
    • Muller, Y.Y.A.1    Christinger, H.W.2    Keyt, B.A.3    De Vos, A.M.4
  • 13
    • 4143136640 scopus 로고    scopus 로고
    • Vascular endothelial growth factor: Basic science and clinical progress
    • Ferrara, N. Vascular Endothelial Growth Factor: Basic Science and Clinical Progress. Endocrine Rev., 2004, 25(4), 581-611.
    • (2004) Endocrine Rev. , vol.25 , Issue.4 , pp. 581-611
    • Ferrara, N.1
  • 14
    • 1642280409 scopus 로고    scopus 로고
    • Diffentiated human podocytes endogeously express an inhibitory isoform of vascular endothelia growth factor (vegf165b) mrna and protein
    • Cui, T.G.; R.R.; Saleem, M.; Matieson, P.W.; Gillatt,D.A.; Bates, D.O.; Harper, S.J. Diffentiated human podocytes endogeously express an inhibitory isoform of vascular endothelia growth factor (VEGF165b) mRNA and protein. Am. J. Physiol-Renal., 2004, 286(4), 767-773.
    • (2004) Am. J. Physiol-Renal. , vol.286 , Issue.4 , pp. 767-773
    • Cui, T.G.1    Saleem, M.2    Matieson, P.W.3    Gillatt, D.A.4    Bates, D.O.5    Harper, S.J.6
  • 15
    • 0026699255 scopus 로고
    • Flt4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines
    • Pajusola K; Aprelikova O; Korhonen J; Kaipainen A; PertovaaraL; Alitalo R; Alitalo K. FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res., 1992, 52(20), 5738-5743.
    • (1992) Cancer Res. , vol.52 , Issue.20 , pp. 5738-5743
    • Pajusola, K.1    Aprelikova, O.2    Korhonen, J.3    Kaipainen, A.4    Pertovaara, L.5    Alitalo, R.6    Alitalo, K.7
  • 16
    • 78650853253 scopus 로고    scopus 로고
    • Recent progress of small molecular vegfr inhibitors as anticancer agents
    • Xu, D.; Wang, T. L.; Sun, L. P.; You, Q. D. Recent progress of small molecular VEGFR inhibitors as anticancer agents. Mini Rev. Med. Chem., 2011, 11(1), 18-31.
    • (2011) Mini Rev. Med. Chem. , vol.11 , Issue.1 , pp. 18-31
    • Xu, D.1    Wang, T.L.2    Sun, L.P.3    You, Q.D.4
  • 17
    • 0037699954 scopus 로고    scopus 로고
    • The biology of vegf and its receptors
    • Ferrara, N.; Gerber, H. P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med., 2003, 9(6), 669-676.
    • (2003) Nat. Med. , vol.9 , Issue.6 , pp. 669-676
    • Ferrara, N.1    Gerber, H.P.2    LeCouter, J.3
  • 18
    • 0034979159 scopus 로고    scopus 로고
    • Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis
    • Dor, Y.; Porat, R.; Keshet, E. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am. J. Physiol. Cell Physiol., 2001, 280(6), C1367-C1374.
    • (2001) Am. J. Physiol. Cell Physiol. , vol.280 , Issue.6
    • Dor, Y.1    Porat, R.2    Keshet, E.3
  • 19
    • 0031039243 scopus 로고    scopus 로고
    • The biology of vascular endothelial growth factor
    • Ferrara, N.; Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev., 1997, 18(1), 4-25.
    • (1997) Endocr. Rev. , vol.18 , Issue.1 , pp. 4-25
    • Ferrara, N.1    Davis-Smyth, T.2
  • 20
    • 0032907687 scopus 로고    scopus 로고
    • Vascular endothelial growth factor (vegf) and its receptors
    • Neufeld, G.; Cohen, T.; Gengrinovitch, S.; Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB. J., 1999, 13(1), 9-22.
    • (1999) FASEB. J. , vol.13 , Issue.1 , pp. 9-22
    • Neufeld, G.1    Cohen, T.2    Gengrinovitch, S.3    Poltorak, Z.4
  • 21
    • 84861539889 scopus 로고    scopus 로고
    • An update on the current and emerging targeted agents in metastatic colorectal cancer
    • Chu, E. An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer. Clin. Colorectal Cancer, 2011, 11(1), 1-13.
    • (2011) Clin. Colorectal Cancer , vol.11 , Issue.1 , pp. 1-13
    • Chu, E.1
  • 22
    • 22244490088 scopus 로고    scopus 로고
    • Identification of novel extracellular signal-regulated kinase docking domain inhibitors
    • Hancock, C. N.; Macias, A.; Lee, E. K.; Yu, S. Y. ; Mackerell, A. D., Jr.; Shapiro, P. Identification of Novel Extracellular Signal-Regulated Kinase Docking Domain Inhibitors. J. Med. Chem., 2005, 48(14), 4586-4595.
    • (2005) J. Med. Chem. , vol.48 , Issue.14 , pp. 4586-4595
    • Hancock, C.N.1    Macias, A.2    Lee, E.K.3    Yu, S.Y.4    Mackerell Jr., A.D.5    Shapiro, P.6
  • 25
    • 0030888185 scopus 로고    scopus 로고
    • The am and fm of calcium signalling
    • Berridge, M.J. The AM and FM of calcium signalling. Nature, 1997, 386(6627), 759-760.
    • (1997) Nature , vol.386 , Issue.6627 , pp. 759-760
    • Berridge, M.J.1
  • 26
    • 33846940789 scopus 로고    scopus 로고
    • Vincristine regulates the phosphorylation of the antiapoptotic protein hsp27 in breast cancer cells
    • Casado, P.; Zuazua-Villar, P.; del Valle, E.; Martinez-Campa, C.; Lazo, P. S.; Ramos, S. Vincristine regulates the phosphorylation of the antiapoptotic protein HSP27 in breast cancer cells. Cancer Lett., 2007, 247(2), 273-282.
    • (2007) Cancer Lett. , vol.247 , Issue.2 , pp. 273-282
    • Casado, P.1    Zuazua-Villar, P.2    Del Valle, E.3    Martinez-Campa, C.4    Lazo, P.S.5    Ramos, S.6
  • 27
    • 29244479188 scopus 로고    scopus 로고
    • Blocking tumor cell migration and invasion with biphenyl isoxazole derivative kribb3, a synthetic molecule that inhibits hsp27 phosphorylation
    • Shin, K. D.; Lee, M. Y. ; Shin, D. S.; Lee, S.; Son, K. H.; Koh, S.; Paik, Y. K.; Kwon, B. M.; Han, D. C. Blocking tumor cell migration and invasion with biphenyl isoxazole derivative KRIBB3, a synthetic molecule that inhibits Hsp27 phosphorylation. J. Biol. Chem., 2005, 280(50), 41439-41448.
    • (2005) J. Biol. Chem. , vol.280 , Issue.50 , pp. 41439-41448
    • Shin, K.D.1    Lee, M.Y.2    Shin, D.S.3    Lee, S.4    Son, K.H.5    Koh, S.6    Paik, Y.K.7    Kwon, B.M.8    Han, D.C.9
  • 28
    • 0034000699 scopus 로고    scopus 로고
    • Vegf receptor signal in tumor angiogenesis
    • McMahon, G. VEGF receptor signal in tumor angiogenesis. Oncologist, 2000, 5, 3-10.
    • (2000) Oncologist , vol.5 , pp. 3-10
    • McMahon, G.1
  • 30
    • 84855655264 scopus 로고    scopus 로고
    • The expanding role of vascular endothelial growth factor inhibitors in ophthalmology
    • Stewart, M. W. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin. Proc., 2012, 87(1), 77-88.
    • (2012) Mayo Clin. Proc. , vol.87 , Issue.1 , pp. 77-88
    • Stewart, M.W.1
  • 31
    • 21744446220 scopus 로고    scopus 로고
    • Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration
    • Ng, E. W. ; Adamis, A. P. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can. J. Ophthalmol., 2005, 40(3), 352-368.
    • (2005) Can. J. Ophthalmol. , vol.40 , Issue.3 , pp. 352-368
    • Ng, E.W.1    Adamis, A.P.2
  • 32
    • 35448952213 scopus 로고    scopus 로고
    • Antiangiogenic agents: An update on small molecule vegfr inhibitors
    • Schenone, S.; Bondavalli, F.; Botta, M. Antiangiogenic Agents: An Update on Small Molecule VEGFR Inhibitors. Curr. Med. Chem., 2007, 14(23), 2495-2516.
    • (2007) Curr. Med. Chem. , vol.14 , Issue.23 , pp. 2495-2516
    • Schenone, S.1    Bondavalli, F.2    Botta, M.3
  • 33
    • 33646417088 scopus 로고    scopus 로고
    • Potent neutralization of vegf biological activities with a fully human antibody fab fragment directed against vegf receptor 2
    • Miao, H. Q.; Hu, K.; Jimenez, X.; Navarro, E.; Zhang, H.; Lu, D.; Ludwig, D. L.; Balderes, P.; Zhu, Z. Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2. Biochem. Biophys. Res. Commun., 2006, 345(1), 438-445.
    • (2006) Biochem. Biophys. Res. Commun. , vol.345 , Issue.1 , pp. 438-445
    • Miao, H.Q.1    Hu, K.2    Jimenez, X.3    Navarro, E.4    Zhang, H.5    Lu, D.6    Ludwig, D.L.7    Balderes, P.8    Zhu, Z.9
  • 34
    • 27944456516 scopus 로고    scopus 로고
    • Managing patients treated with bevacizumab combination therapy
    • Gordon, M. S.; Cunningham, D. Managing patients treated with bevacizumab combination therapy. Oncology, 2005, 69 Suppl 3, 25-33.
    • (2005) Oncology , vol.69 , Issue.SUPPL. 3 , pp. 25-33
    • Gordon, M.S.1    Cunningham, D.2
  • 35
    • 84893616814 scopus 로고    scopus 로고
    • Advances in targeted therapy of colorectal cancer by bavacizumab
    • Luo, C.; Ying, J. Advances in Targeted Therapy of Colorectal Cancer by Bavacizumab. Chinese General Practice, 2011, 29, 3407-3409.
    • (2011) Chinese General Practice , vol.29 , pp. 3407-3409
    • Luo, C.1    Ying, J.2
  • 37
    • 35548934659 scopus 로고    scopus 로고
    • Alphaplgf: A new kid on the antiangiogenesis block
    • Jain, R. K.; Xu, L. alphaPlGF: A new kid on the antiangiogenesis block. Cell, 2007, 131(3), 443-445.
    • (2007) Cell , vol.131 , Issue.3 , pp. 443-445
    • Jain, R.K.1    Xu, L.2
  • 38
    • 84861307333 scopus 로고    scopus 로고
    • Inhibition of placenta growth factor with tb-403: A novel antiangiogenic cancer therapy
    • Nielsen, D. L.; Sengelov, L. Inhibition of placenta growth factor with TB-403: A novel antiangiogenic cancer therapy. Expert Opin. Biol. Ther., 2012, 12(6), 795-804.
    • (2012) Expert Opin. Biol. Ther. , vol.12 , Issue.6 , pp. 795-804
    • Nielsen, D.L.1    Sengelov, L.2
  • 39
    • 80053041612 scopus 로고    scopus 로고
    • Monoclonal antibody tb-403: A first-in-human, phase i, double-blind, dose escalation study directed against placental growth factor in healthy male subjects
    • Martinsson-Niskanen, T.; Riisbro, R.; Larsson, L.; Winstedt, L.; Stenberg, Y.; Pakola, S.; Stassen, J. M.; Glazer, S. Monoclonal antibody TB-403: A first-in-human, Phase I, double-blind, dose escalation study directed against placental growth factor in healthy male subjects. Clin. Ther., 2011, 33(9), 1142-1149.
    • (2011) Clin. Ther. , vol.33 , Issue.9 , pp. 1142-1149
    • Martinsson-Niskanen, T.1    Riisbro, R.2    Larsson, L.3    Winstedt, L.4    Stenberg, Y.5    Pakola, S.6    Stassen, J.M.7    Glazer, S.8
  • 41
    • 33746910190 scopus 로고    scopus 로고
    • Pegaptanib for the treatment of age-related macular degeneration
    • Zhou, B.; Wang, B. Pegaptanib for the treatment of age-related macular degeneration. Exp. Eye Res., 2006, 83(3), 615-619.
    • (2006) Exp. Eye Res. , vol.83 , Issue.3 , pp. 615-619
    • Zhou, B.1    Wang, B.2
  • 42
    • 3242734630 scopus 로고    scopus 로고
    • Aptamers, intramers, and vascular endothelial growth factor
    • Waheed, N.K.;Miller, J.W. Aptamers, intramers, and vascular endothelial growth factor. Int. Ophthalmol. Clin., 2004, 44(3), 11-22.
    • (2004) Int. Ophthalmol. Clin. , vol.44 , Issue.3 , pp. 11-22
    • Waheed, N.K.1    Miller, J.W.2
  • 43
    • 67349167635 scopus 로고    scopus 로고
    • Discovery and development of the g-rich oligonucleotide as1411 as a novel treatment for cancer
    • Bates, P. J.; Laber, D. A.; Miller, D. M.; Thomas, S. D.; Trent, J. O. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp. Mol. Pathol., 2009, 86(3), 151-164.
    • (2009) Exp. Mol. Pathol. , vol.86 , Issue.3 , pp. 151-164
    • Bates, P.J.1    Laber, D.A.2    Miller, D.M.3    Thomas, S.D.4    Trent, J.O.5
  • 44
    • 77950145605 scopus 로고    scopus 로고
    • Aptamer-based tumor-targeted drug delivery for photodynamic therapy
    • Shieh, Y. A.; Yang, S. J.; Wei, M. F.; Shieh, M. J. Aptamer-based tumor-targeted drug delivery for photodynamic therapy. ACS Nano., 2010, 4(3), 1433-1442.
    • (2010) ACS Nano. , vol.4 , Issue.3 , pp. 1433-1442
    • Shieh, Y.A.1    Yang, S.J.2    Wei, M.F.3    Shieh, M.J.4
  • 45
    • 2542465496 scopus 로고    scopus 로고
    • Department of Health & Human Services: FDA approves Eylea for eye disorder in older people. (Accessed Nov 18
    • U.S. Food and Drug Administration, U.S. Department of Health & Human Services: FDA approves Eylea for eye disorder in older people. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280601.htm (Accessed Nov 18, 2011)
    • (2011) U.S. Food and Drug Administration U.S
  • 46
    • 57649229413 scopus 로고    scopus 로고
    • Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using qsar and docking
    • Du, J.; Lei, B.; Qin, J. ; Liu, H. ; Yao, X. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking. J. Mol. Graph. Model, 2009, 27(5), 642-654.
    • (2009) J. Mol. Graph. Model , vol.27 , Issue.5 , pp. 642-654
    • Du, J.1    Lei, B.2    Qin, J.3    Liu, H.4    Yao, X.5
  • 47
    • 2542465496 scopus 로고    scopus 로고
    • Department of Health & Human Services: FDA approves new treatment for rare form of thyroid cancer. (Accessed April 7
    • U.S. Food and Drug Administration, U.S. Department of Health & Human Services: FDA approves new treatment for rare form of thyroid cancer. http://www.fda.gov/NewsEvents/Newsroom/Press Announcements/ucm250168.htm (Accessed April 7, 2011)
    • (2011) U.S. Food and Drug Administration U.S
  • 48
    • 57649229413 scopus 로고    scopus 로고
    • Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using qsar and docking
    • Du, J.; Lei, B.; Qin, J. ; Liu, H. ; Yao, X. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking. J. Mol. Graph. Model, 2009, 27(5), 642-654.
    • (2009) J. Mol. Graph. Model , vol.27 , Issue.5 , pp. 642-654
    • Du, J.1    Lei, B.2    Qin, J.3    Liu, H.4    Yao, X.5
  • 49
    • 49449117755 scopus 로고    scopus 로고
    • Discovery of 5-[ [4-[(2,3-dimethyl-2hindazol-6-yl)methylamino]-2- pyrimidinyl]amino]-2-methyl benzenesulf-onamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor
    • Cheung, M.; Kumar, R. Discovery of 5-[ [4-[(2,3-Dimethyl-2Hindazol-6-yl) methylamino]-2-pyrimidinyl]amino]-2-methyl benzenesulf-onamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor. J. Med. Chem., 2008, 51(15), 4632-4640.
    • (2008) J. Med. Chem. , vol.51 , Issue.15 , pp. 4632-4640
    • Cheung, M.1    Kumar, R.2
  • 51
    • 47949099628 scopus 로고    scopus 로고
    • Modes of resistance to anti-angiogenic therapy
    • Bergers, G.; Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer, 2008, 8(8), 592-603.
    • (2008) Nat. Rev. Cancer , vol.8 , Issue.8 , pp. 592-603
    • Bergers, G.1    Hanahan, D.2
  • 52
    • 84878325052 scopus 로고    scopus 로고
    • Beyond anti-vegf: Dual-targeting antiangiogenic and antiproliferative therapy
    • Chen, C. T.; Hung, M. C. Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy. Am. J. Transl. Res., 2013, 5(4), 393-403.
    • (2013) Am. J. Transl. Res. , vol.5 , Issue.4 , pp. 393-403
    • Chen, C.T.1    Hung, M.C.2
  • 53
    • 77957065782 scopus 로고    scopus 로고
    • Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer
    • Wang, B.; Rosano, J. M.; Cheheltani, R.; Achary, M. P.; Kiani, M. F. Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer. Expert Opin. Drug Deliv., 2010, 7(10), 1159-1173.
    • (2010) Expert Opin. Drug Deliv. , vol.7 , Issue.10 , pp. 1159-1173
    • Wang, B.1    Rosano, J.M.2    Cheheltani, R.3    Achary, M.P.4    Kiani, M.F.5
  • 57
    • 84863021288 scopus 로고    scopus 로고
    • Plumbagin inhibits tumour angiogenesis and tumour growth through the ras signalling pathway following activation of the vegf receptor-2
    • Lai, L.; Liu, J.; Zhai, D.; Lin, Q.; He, L.; Dong, Y. ; Zhang, J.; Lu, B. ; Chen, Y. ; Yi, Z. ; Liu, M. Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor-2. Br. J. Pharmacol., 2012, 165(4b), 1084-1096.
    • (2012) Br. J. Pharmacol. , vol.165 , Issue.4 B , pp. 1084-1096
    • Lai, L.1    Liu, J.2    Zhai, D.3    Lin, Q.4    He, L.5    Dong, Y.6    Zhang, J.7    Lu, B.8    Chen, Y.9    Yi, Z.10    Liu, M.11
  • 59
    • 84863814724 scopus 로고    scopus 로고
    • Vemurafenib in patients with braf v600e mutation-positive advanced melanoma
    • Ravnan, M. C.; Matalka, M. S. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Clin. Ther., 2012, 34(7), 1474-1486.
    • (2012) Clin. Ther. , vol.34 , Issue.7 , pp. 1474-1486
    • Ravnan, M.C.1    Matalka, M.S.2
  • 61
    • 84872361487 scopus 로고    scopus 로고
    • Dabrafenib and its potential for the treatment of metastatic melanoma
    • Menzies A.M.; Long G.V.; Murali R. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des. Devel. Ther., 2012, 6, 391-405.
    • (2012) Drug Des. Devel. Ther. , vol.6 , pp. 391-405
    • Menzies, A.M.1    Long, G.V.2    Murali, R.3
  • 62
    • 7044234484 scopus 로고    scopus 로고
    • Different signalling pathways regulate vegf and il-8 expression in breast cancer: Implications for therapy
    • Chelouche-Lev, D.; Miller, C. P. ; Tellez, C.; Ruiz, M. ; Bar-Eli, M. ; Price, J. E. Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy. Eur. J. Cancer, 2004, 40(16), 2509-2518.
    • (2004) Eur. J. Cancer , vol.40 , Issue.16 , pp. 2509-2518
    • Chelouche-Lev, D.1    Miller, C.P.2    Tellez, C.3    Ruiz, M.4    Bar-Eli, M.5    Price, J.E.6
  • 63
    • 33745859743 scopus 로고    scopus 로고
    • The braf-mapk signaling pathway is essential for cancer-immune evasion in human melanoma cells
    • Sumimoto, H.; Imabayashi, F.; Iwata, T.; Kawakami, Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med., 2006, 203(7), 1651-1656.
    • (2006) J. Exp. Med. , vol.203 , Issue.7 , pp. 1651-1656
    • Sumimoto, H.1    Imabayashi, F.2    Iwata, T.3    Kawakami, Y.4
  • 66
    • 84855590085 scopus 로고    scopus 로고
    • Targeting the ras pathway in melanoma
    • Ji, Z.; Flaherty, K. T.; Tsao, H. Targeting the RAS pathway in melanoma. Trends Mol. Med., 2012, 18(1), 27-35.
    • (2012) Trends Mol. Med. , vol.18 , Issue.1 , pp. 27-35
    • Ji, Z.1    Flaherty, K.T.2    Tsao, H.3
  • 70
    • 84893531063 scopus 로고    scopus 로고
    • American Society of Clinical Oncology (ASCO). 2012 ASCO Annual Meeting: METRIC phase III study: Efficacy of Trametinib (T), a Potent and Selective MEK Inhibitor (MEKi), In Progressionfree Survival (PFS) and Overall Survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma MM) (Accessed 2012).
    • American Society of Clinical Oncology (ASCO). 2012 ASCO Annual Meeting: METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progressionfree survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM). http://www.asco.org/ASCOv2/Meetings/ Abstracts?abstractID=96304&confID=114&vmvie w=abst-detail-view (Accessed 2012).
  • 73
    • 84865113022 scopus 로고    scopus 로고
    • Usnic acid inhibits breast tumor angiogenesis and growth by suppressing vegfr2-mediated akt and erk1/2 signaling pathways
    • Song, Y.; Dai, F.; Zhai, D.; Dong, Y.; Zhang, J.; Lu, B.; Luo, J.; Liu, M.; Yi, Z. Usnic acid inhibits breast tumor angiogenesis and growth by suppressing VEGFR2-mediated AKT and ERK1/2 signaling pathways. Angiogenesis, 2012, 15(3), 421-432.
    • (2012) Angiogenesis , vol.15 , Issue.3 , pp. 421-432
    • Song, Y.1    Dai, F.2    Zhai, D.3    Dong, Y.4    Zhang, J.5    Lu, B.6    Luo, J.7    Liu, M.8    Yi, Z.9
  • 79
    • 0032515047 scopus 로고    scopus 로고
    • Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/akt signal transduction pathway. Requirement for flk-1/kdr activation
    • Gerber, H. P.; McMurtrey, A.; Kowalski, J.; Yan, M.; Keyt, B. A.; Dixit, V.; Ferrara, N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem., 1998, 273(46), 30336-30343.
    • (1998) J. Biol. Chem. , vol.273 , Issue.46 , pp. 30336-30343
    • Gerber, H.P.1    McMurtrey, A.2    Kowalski, J.3    Yan, M.4    Keyt, B.A.5    Dixit, V.6    Ferrara, N.7
  • 80
    • 71549119169 scopus 로고    scopus 로고
    • Wortmannin potentiates roscovitine-induced growth inhibition in human solid tumor cells by repressing pi3k/akt pathway
    • Zhang, F.; Zhang, T.; Jiang, T.; Zhang, R.; Teng, Z. H.; Li, C.; Gu, Z. P.; Mei, Q. Wortmannin potentiates roscovitine-induced growth inhibition in human solid tumor cells by repressing PI3K/Akt pathway. Cancer Lett., 2009, 286(2), 232-239.
    • (2009) Cancer Lett. , vol.286 , Issue.2 , pp. 232-239
    • Zhang, F.1    Zhang, T.2    Jiang, T.3    Zhang, R.4    Teng, Z.H.5    Li, C.6    Gu, Z.P.7    Mei, Q.8
  • 81
    • 0142227019 scopus 로고    scopus 로고
    • Targeting the pi3k-akt pathway in human cancer: Rationale and promise
    • Luo, J.; Manning, B. D.; Cantley, L. C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell., 2003, 4(4), 257-262.
    • (2003) Cancer Cell. , vol.4 , Issue.4 , pp. 257-262
    • Luo, J.1    Manning, B.D.2    Cantley, L.C.3
  • 83
    • 84866313204 scopus 로고    scopus 로고
    • Zebrafish lead the way in control of vascular permeability
    • Arbiser, J. L. Zebrafish lead the way in control of vascular permeability. Blood, 2012, 120(11), 2162-2164.
    • (2012) Blood , vol.120 , Issue.11 , pp. 2162-2164
    • Arbiser, J.L.1
  • 84
    • 0025201019 scopus 로고
    • Selective inhibition of receptor-coupled phospholipase c-dependent processes in human platelets and polymorphonuclear neutrophils
    • Bleasdale, J. E.; Thakur, N. R.; Gremban, R. S.; Bundy, G. L.; Fitzpatrick, F. A.; Smith, R. J.; Bunting, S. Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J. Pharmacol. Exp. Ther., 1990, 255(2), 756-768.
    • (1990) J. Pharmacol. Exp. Ther. , vol.255 , Issue.2 , pp. 756-768
    • Bleasdale, J.E.1    Thakur, N.R.2    Gremban, R.S.3    Bundy, G.L.4    Fitzpatrick, F.A.5    Smith, R.J.6    Bunting, S.7
  • 85
    • 79955943879 scopus 로고    scopus 로고
    • Vegf-induced retinal angiogenic signaling is critically dependent on ca (2)(+) signaling by ca(2)(+)/calmodulin-dependent protein kinase ii
    • Banumathi, E.; O'Connor, A.; Gurunathan, S.; Simpson, D. A.; McGeown, J. G.; Curtis, T. M. VEGF-induced retinal angiogenic signaling is critically dependent on Ca(2)(+) signaling by Ca(2)(+)/calmodulin-dependent protein kinase II. Invest. Ophthalmol. Vis. Sci., 2011, 52(6), 3103-3111.
    • (2011) Invest. Ophthalmol. Vis. Sci. , vol.52 , Issue.6 , pp. 3103-3111
    • Banumathi, E.1    O'Connor, A.2    Gurunathan, S.3    Simpson, D.A.4    McGeown, J.G.5    Curtis, T.M.6
  • 86
    • 33744794029 scopus 로고    scopus 로고
    • Vegf-e activates endothelial nitric oxide synthase to induce angiogenesis via cgmp and pkg-independent pathways
    • Cudmore, M.; Ahmad, S.; Al-Ani, B.; Hewett, P.; Ahmed, S.; Ahmed, A. VEGF-E activates endothelial nitric oxide synthase to induce angiogenesis via cGMP and PKG-independent pathways. Biochem. Biophys. Res. Commun., 2006, 345(4), 1275-1282.
    • (2006) Biochem. Biophys. Res. Commun. , vol.345 , Issue.4 , pp. 1275-1282
    • Cudmore, M.1    Ahmad, S.2    Al-Ani, B.3    Hewett, P.4    Ahmed, S.5    Ahmed, A.6
  • 87
    • 85037067799 scopus 로고    scopus 로고
    • In silico identification of bim-1 (2-methyl-1h-indol-3-yl) as a potential therapeutic agent against elevated protein kinase c beta associated diseases
    • Umar, S.; Nayab, N.; Yasir, W.; Nazia, C.; Bhatti, H. T.; Urooj, S.; Waheed, H.; Ashraf, M.; Khan Naizi, U.H. In silico identification of BIM-1 (2-methyl-1H-indol-3-yl) as a potential therapeutic agent against elevated protein kinase C beta associated diseases. Afr. J. Biotechnol., 2012, 11(19), 4434-4441.
    • (2012) Afr. J. Biotechnol. , vol.11 , Issue.19 , pp. 4434-4441
    • Umar, S.1    Nayab, N.2    Yasir, W.3    Nazia, C.4    Bhatti, H.T.5    Urooj, S.6    Waheed, H.7    Ashraf, M.8    Khan Naizi, U.H.9
  • 88
    • 24644488646 scopus 로고    scopus 로고
    • Crystal structure of the catalytic domain of human atypical protein kinase c-iota reveals interaction mode of phosphorylation site in turn motif
    • Messerschmidt, A.; Macieira, S.; Velarde, M.; Badeker, M.; Benda, C.; Jestel, A.; Brandstetter, H.; Neuefeind, T.; Blaesse, M. Crystal structure of the catalytic domain of human atypical protein kinase C-iota reveals interaction mode of phosphorylation site in turn motif. J. Mol. Biol., 2005, 352(4), 918-931.
    • (2005) J. Mol. Biol. , vol.352 , Issue.4 , pp. 918-931
    • Messerschmidt, A.1    Macieira, S.2    Velarde, M.3    Badeker, M.4    Benda, C.5    Jestel, A.6    Brandstetter, H.7    Neuefeind, T.8    Blaesse, M.9
  • 89
    • 33751570046 scopus 로고    scopus 로고
    • Structure of the catalytic domain of human protein kinase c beta ii complexed with a bisindolylmaleimide inhibitor
    • Grodsky, N.; Li, Y.; Bouzida, D.; Love, R.; Jensen, J.; Nodes, B.; Nonomiya, J.; Grant, S. Structure of the catalytic domain of human protein kinase C beta II complexed with a bisindolylmaleimide inhibitor. Biochemistry, 2006, 45(47), 13970-13981.
    • (2006) Biochemistry , vol.45 , Issue.47 , pp. 13970-13981
    • Grodsky, N.1    Li, Y.2    Bouzida, D.3    Love, R.4    Jensen, J.5    Nodes, B.6    Nonomiya, J.7    Grant, S.8
  • 92
    • 33646145320 scopus 로고    scopus 로고
    • Angiotensin ii stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes
    • Kang, Y. S.; Park, Y. G.; Kim, B. K.; Han, S. Y.; Jee, Y. H.; Han, K. H.; Lee, M. H.; Song, H. K.; Cha, D. R.; Kang, S. W.; Han, D. S. Angiotensin II stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes. J. Mol. Endocrinol., 2006, 36(2), 377-388.
    • (2006) J. Mol. Endocrinol. , vol.36 , Issue.2 , pp. 377-388
    • Kang, Y.S.1    Park, Y.G.2    Kim, B.K.3    Han, S.Y.4    Jee, Y.H.5    Han, K.H.6    Lee, M.H.7    Song, H.K.8    Cha, D.R.9    Kang, S.W.10    Han, D.S.11


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.